| Symbol | VRCA |
|---|---|
| Name | VERRICA PHARMACEUTICALS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 44 W. GAY ST.,SUITE 400, WEST CHESTER, Pennsylvania, 19380, United States |
| Telephone | +1 484 453-3300 |
| Fax | — |
| — | |
| Website | https://www.verrica.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001660334 |
| Description | Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts. Additional info from NASDAQ: |
Zawitz David 🟢 acquired 6.0K shares of Verrica Pharmaceuticals Inc. (VRCA) at $4.98 Transaction Date: Aug 17, 2026 | Filing ID: 000004
Read moreRieger Jayson 🟢 acquired 25.0K shares of Verrica Pharmaceuticals Inc. (VRCA) at $5.06 Transaction Date: Aug 14, 2026 | Filing ID: 000005
Read moreRosenberg Noah L. 🟢 acquired 6.2K shares of Verrica Pharmaceuticals Inc. (VRCA) at $4.92 Transaction Date: Aug 17, 2026 | Filing ID: 000005
Read moreKirby John J. 🟢 acquired 5.0K shares of Verrica Pharmaceuticals Inc. (VRCA) at $4.93 Transaction Date: Aug 18, 2026 | Filing ID: 000003
Read moreVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Read moreEichenfield Lawrence 🟢 acquired 16.0K shares (1 derivative) of Verrica Pharmaceuticals Inc. (VRCA) at $6.04 Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read moreNguyen Diem 🟢 acquired 16.0K shares (1 derivative) of Verrica Pharmaceuticals Inc. (VRCA) at $6.04 Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read morePRYGOCKI MARK A SR 🟢 acquired 16.0K shares (1 derivative) of Verrica Pharmaceuticals Inc. (VRCA) at $6.04 Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read moreZawitz David 🟢 acquired 171.3K shares (1 derivative) of Verrica Pharmaceuticals Inc. (VRCA) at $8.21 ($1.4M) Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read moreRieger Jayson 🟢 acquired 512.3K shares (1 derivative) of Verrica Pharmaceuticals Inc. (VRCA) at $8.21 ($4.2M) Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07637734 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-… | Phase3 | Common Warts | Not_Yet_Recruiting | 2026-06-01 | 2027-10-01 | ClinicalTrials.gov |
| NCT07457918 | Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients W… | Phase3 | Common Warts (Verruca Vulgaris) | Recruiting | 2026-03-11 | 2028-05-22 | ClinicalTrials.gov |
| NCT07246590 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-… | Phase3 | Common Warts | Recruiting | 2025-12-17 | 2027-06-01 | ClinicalTrials.gov |
| NCT05188729 | Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma | Phase2 | Basal Cell Carcinoma | Completed | 2022-02-01 | 2024-04-15 | ClinicalTrials.gov |
| NCT03981822 | A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Wa… | Phase2 | Condylomata Acuminata | Completed | 2019-06-25 | 2020-07-08 | ClinicalTrials.gov |
| NCT03487549 | Cantharidin and Occlusion in Verruca Epithelium | Phase2 | Common Wart | Completed | 2018-03-27 | 2019-07-15 | ClinicalTrials.gov |
| NCT03377790 | Cantharidin Application in Molluscum Patients-1 | Phase3 | Molluscum Contagiosum | Completed | 2018-03-21 | 2018-11-26 | ClinicalTrials.gov |
| NCT03377803 | Cantharidin Application in Molluscum Patients | Phase3 | Molluscum Contagiosum | Completed | 2018-02-14 | 2018-09-26 | ClinicalTrials.gov |
| NCT03186378 | Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosu… | Phase2 | Molluscum Contagiosum | Completed | 2017-06-08 | 2018-06-25 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vehicle (US) / Vehicle (Japan) | Other | Phase PHASE3 | Common Warts | NOT_YET_RECRUITING | NCT07637734 |
| VP-102 (US) / TO-208 (Japan) | Other | Phase PHASE3 | Common Warts | NOT_YET_RECRUITING | NCT07637734 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | RECRUITING | NCT07457918 |
| VP-102 with applicator | Other | Phase PHASE2 | Molluscum Contagiosum | COMPLETED | NCT03186378 |
| Placebo -Topical Film Forming Solution without VP-102 | Other | Phase PHASE3 | Molluscum Contagiosum | COMPLETED | NCT03377803 |
| VP-102 - Cantharidin, Topical Film Forming Solution | Other | Phase PHASE3 | Molluscum Contagiosum | COMPLETED | NCT03377803 |
| Placebo -Topical Film Forming Solution without VP-102 | Other | Phase PHASE3 | Molluscum Contagiosum | COMPLETED | NCT03377790 |
| VP-102 - Cantharidin, Topical Film Forming Solution | Other | Phase PHASE3 | Molluscum Contagiosum | COMPLETED | NCT03377790 |
| Placebo | Other | Phase PHASE2 | Condylomata Acuminata | COMPLETED | NCT03981822 |
| VP-102 and applicator | Other | Phase PHASE2 | Condylomata Acuminata | COMPLETED | NCT03981822 |
| VP-102 Cantharidin, topical film forming solution | Other | Phase PHASE2 | Common Wart | COMPLETED | NCT03487549 |
| VP-102 Cantharidin topical film forming solution | Other | Phase PHASE2 | Common Wart | COMPLETED | NCT03487549 |
| Part 2: VP-315 3 Day Dosing/Week - Split Dose | Other | Phase PHASE2 | Basal Cell Carcinoma | COMPLETED | NCT05188729 |
| Part 2: VP-315 2 Day Dosing/Week - Split Dose | Other | Phase PHASE2 | Basal Cell Carcinoma | COMPLETED | NCT05188729 |
| Part 2: VP-315 3 Day Dosing/Week - No Loading Dose | Other | Phase PHASE2 | Basal Cell Carcinoma | COMPLETED | NCT05188729 |
| Part 2: VP-315 3 Day Dosing/Week - Loading Dose | Other | Phase PHASE2 | Basal Cell Carcinoma | COMPLETED | NCT05188729 |
| Part 1: VP-315 3 Day Dosing/Week | Other | Phase PHASE2 | Basal Cell Carcinoma | COMPLETED | NCT05188729 |
| Vehicle | Other | Phase PHASE3 | Common Warts | RECRUITING | NCT07246590 |
| VP-102 | Other | Phase PHASE3 | Common Warts | RECRUITING | NCT07246590 |
| Cantharidin | Other | Phase PHASE3 | Common Warts (Verruca Vulgaris) | NOT_YET_RECRUITING | NCT07457918 |
| Part 2: VP-315 3 Day Dosing/Week - Split Dose | DRUG | Phase PHASE2 | Basal Cell Carcinoma | COMPLETED | NCT05188729 |
| Part 2: VP-315 2 Day Dosing/Week - Split Dose | DRUG | Phase PHASE2 | Basal Cell Carcinoma | COMPLETED | NCT05188729 |
| Part 2: VP-315 3 Day Dosing/Week - No Loading Dose | DRUG | Phase PHASE2 | Basal Cell Carcinoma | COMPLETED | NCT05188729 |
| Part 2: VP-315 3 Day Dosing/Week - Loading Dose | DRUG | Phase PHASE2 | Basal Cell Carcinoma | COMPLETED | NCT05188729 |
| Part 1: VP-315 3 Day Dosing/Week | DRUG | Phase PHASE2 | Basal Cell Carcinoma | COMPLETED | NCT05188729 |